semiconductor Mark you, off to results to to a first and year-over-year. began the we the strong we fiscal you Life XXXX. million, a to XX% And Sciences in plan. was our from We're everyone. of of sequentially on performance report start afternoon up delivered pleased quarter and the quarter, at witness to right equipment revenue in X% QX In year Thank $XXX good We're meaningful start uplift coming the market. with in that
yet we've that Our strength and we very year have QX developed the the of momentum in markets, capture. customer strong much these products supports our a to confidence as and serve another growth markets, services
mostly said, That range the we best articulate it's in coronavirus. and timing. a to you we'll how of the with what I in weeks, near-term, business, to vary Today impact address uncertainty prudent Lindon do outcomes share due and we're our to to about the of coming our that thinking the anticipate you will about
subsegments and to in made and We forma business essentially in our guidance a intended consistent we as was $XX where Sciences we'd Sciences. QX goals progress Revenue XXXX. solid order recap million accomplished starting for our Life XX% pro significant our a and now year-over-year. we give expectations I'll was of growth of came with meet what forecasted. organic showing for we quarter Life with both across
made by to business. higher-margin the and more-profitable a Sample with year-end Management. start we a our operating we progress support QX hit review return double-digit objective Sample our I'll Management, that promise of targets against In growth for to
growth and priorities terms our on for Management, Sample In we're focused of profitability.
a comment make But let before growth, gross about I margin progress. our me talk about
For most margin XX%. of of the struggled of approximately years we've gross past the get of out range couple to
pressure spending, not material undue control. Our was from performance our pricing but or that rather margin uncontrollable are operational under issues
the and to past say we've As a In management gross six implemented calls, I'm we've over now meaningful some just pleased QX, basis points organizational delivered and past another over changes that some XXX to XXXX. months, demonstrating QX, we margin full improvement said in on progress. we're XX%, above
near-term be by declaring victory which to for XXXX, that still XX% in of but can the and inside as target of to not a We're already solidly we're delivered, improvement XX% was XX% to XXXX. there's operate exceed range our much operating target we're on path here range
note, came to of the Twinbank the BX increase shipments of as well stores. automated as systems, improvements the volume large Just predominantly Cryo the from in
we're at $XX revenue quarter up line X% revenue by year. Sample the to grow our expectations. Second, in million, least this and Management year-over-year determined with X% was in
our high-value longer-term on mentioned have sales growth. will last call, capability on refocused more we that As opportunities more to and organization we've provide added our
few a examples. are Here
demonstrate that We the Cryo serves opportunity. and therapy cell continue gene to the space growth in
of and four own another added those to customer our bringing We multiple new systems. now XX customers count customers, XX
to As the It our of XX be but largest confidence and somewhat and of for have cell hold, must that momentum storage, IVF leading market an for BX we therapy gene up retrieval pick that one business, management, continue systems line for and proper engaged have institutions indicator adoption our a a included takes it our that quarter begun in will units this capability has for product research we sample Cryo innovative as protection. additional and Cryogenic of are this great company. believe lumpy ever momentum, booking orders was QX to
and on-site management service far institutions and we academic has about In oversubscribed as some we with perform their challenges. recommendations that large so outreach work been new sample inventory hospitals, a and well and to launched QX, received assessments
offering to the segment. target developed it's we has that this to our market that Investor will service you that one more confident at particularly meaningfully believe, add identified revenue of a in well but markets second are begin we And to We initiative for half, our adapted importantly, we've Day. this
for a management and patients offering, trials that adding clinical sponsors. security in sample To sample are of And engaged in and value by more clinical new X-million-sample the date, large who enrolled from sample organization and management. dramatically in a solution we we've trials new and passed and delivery samples for XXX reducing of accuracy quality than we're research retrieval pharmaceutical and improving cycles provides milestone level our handling
two opportunities physical solution Each a storage, logistics the services of need of informatics sample last inventory. these the management robust for and include for
time likely we with confidence only maintain year programs. a sequential anticipate early We to will from X/X for results and gain growth results we XX% than by for the modest guidance of again take the begin be still that will take in investments digits more the these growth bit more before more growth to growth see of target but the in to QX, we single of have year-over-year It our high but these of we'll get to QX shift it QX. back to hold,
we We our current are opportunities summarize, that with we recovery in high To started of business Management, us. were and confident execution in on-plan front the in solid position same results our Sample QX are mode. trajectory. remain exactly of we're the a QX this and by energized in
organically strong over years. impressive consistent the growth another GENEWIZ. delivered year-over-year with and in trajectory $XX up Revenue also We few past XX% quarter the was at million
few we next-generation usually was a for sequencing, sequencing and for and XX% down powered a reduced measurements though holidays was high-quality QX, still quarter with share XX% QX growth as continue growth demand some which U.S. as lighter year-over-year. of Sanger by overnight percent our delivered offerings. fast-turn gain Sanger up year-over-year service QX the is European to the from
storage build-out and of our as new is advance capacity XXX We we in functioning capability the our another Europe this customers and be lab of U.S. fully synthesis added co-located Indianapolis with facility. We and formation to main spring. the our intend in we which continued sample aggressive
importantly, Most recognize bring critical research provide. who in business continue from to helping technologies our that we new solve groups, breakthrough securing our scientific challenges customers market innovations to we
in organizations the scientific of epidemic. note reputation, Immediately, GENEWIZ contacted for And it's the global in and GENEWIZ looking Coronavirus, of community. after investigation outbreak carries was the this several by profile to international the help important the that
in continents. fully the disease of During control they've different been few centers numerous for on including three support organizations engaged past weeks,
Our and synthesizing outbreak, and Coronavirus proteins the China services antibodies. of fragments vaccines that U.S. in code of of for development therapeutic in of are of as Coronavirus the teams the synthesizing well will used and and genome, the genes numerous understanding the that other detection diagnosis production be providing as
teams who're We're to combat we trust in fully important Our around and demand this clock consider the the laboratories of this service and high fortunate the of proud engaged of and support the in are epidemic. have endeavor. contribution and our scientists ourselves to working are
on-site holidays, GENEWIZ been New for and returning the Except the that's the is will at our from China team throughout least until labs away to extended team Monday, from Chinese be rest restricted XX. February work our operations of Year
trajectory want by I Before do and that's note my significant I cell the of Life to Sciences seeing make work. about business, we're the conclude gene comments growth driven therapy
the more that from doubled. a in contribution XXXX a of of our than number XX% Although more significantly, and increases cell portfolio, we small estimate calendar derived our XX% customers GENEWIZ more gene in than grew from business still relatively Management which proforma and part year-over-year; therapy than Sample
approximately $XX set XXXX In years million come. total, looks therapy subsegment drive cell was and to in outsized to and revenue particular continued growth for gene this
the our the meet XXXX. delivering We're in change on exactly which Sciences Sample business that implementing we for commitments is structural business, expect. Management All-in our are Life results to track
capabilities team. to and We work seeing are and in new we still that be improvements. impressed the by for the we the GENEWIZ we're investments for we we performance to continue well-placed have making geographic Similarly believe are strong dedicated and work do And this of doing expansion. but
than who to share equipment. the to quarter-over-quarter a of once also lot design ago. from dynamic serve again wins we of had XX% $XXX another as new discuss a was We quarter We gains revenue adding exhibit by companies market up higher Semiconductor next-generation segment. continue have million different other quarter QX side the one XX this same year process X% into and strong on
quarter. QX revenue these significant of the another is QX, more value this which our also levels we product deliver was portfolio, that new which point XXXX we quarter, is semiconductor What's of record that was the of to in in our are levels and the unique peak is at June essentially equipment market. We it delivered poised the highlights performance. believe fueling peak
and high nodes. revenue watermark product for CCS foundry spending adoption records powered These by critical are device
for remains also well-below even packaging and not peak benefits spending, our have advanced automation the robots more demand drives memory of levels. yet We which and systems seen
packaging advanced point to The return recover, and have or is fully a records remain relaxes a set to if new before headroom even we should do bit. spending they we strong still prior revenue even levels foundry memory when
different is We have a track semiconductor many our sweet allows position very from equipment each outperform which share supported robust on area and to strong we're market. technology trends us and again spot, the benefits once by
business our automation, and color some from contamination specific major give I'll packaging Semiconductor solutions. control drivers, tool advanced
now automation squarely our business. are is in still X September. quarter We more the OEM from than in our And with an although peak, consistent the prior you've the approximately sequential to Tier XX% forecast on wafer of in and We heels middle a grew in is vacuum robots growth our of XX% increases upturn June sequentially this about. of robots XX% revenue March we lower increase heard the anticipate automation
million solid flat the market to a design this was for modules QX for position new packaging market. lid nonetheless, soft continues automotive various $XX market on new packaging in XXXX wins advanced automation keeping six with had as keeping us at Advanced with develop. We,
million broadening base shipped to food was foundry of XX% and and a the September, million our of we're Solutions foundry. compared up share of a we we've the in business. Control that the late in you ramp December beyond still jumped but applications and $XX to were Coming had X-nanometer And with quarter quarter much for quarter Contamination December the with off to that's volume in $XX about of The customer cleaners one installations, X majority ago. year for record seeing
yet all all In who in penetration for the QX, technologies the were market more technology to not CCS just at adopting who five are now customers These signs node. we customers XX-nanometer new our extending opportunity. future promising added Asia, are another
another for the March very for outlook business same approximately is Our the QX. in CCS at levels quarter as strong revenue
cycle. these market If way We portfolio we equipment; grew semiconductor for We've one down while and leave from times and it's peak report Semiconductor technology and a a a is which with you still now, takeaway valuable in was product our the the this. in in in life off. a unique constructed semiconductor year XXXX, long
is ago, We are phases secure peak early business XX, The X-nanometer we a revenue nodes during we levels. stronger. business at design position the is X that and our have today technology historical of and won years and getting
the much design, design production perfectly mix. close more their approach design of remains perfect that today, process same an with and there years the are the technology down lock to manufacturability in R&D way, same, we capability. we're future OEMs and securing through Only many the Our a collaboration in build in volume leaders with collaborate partnership today our advance win Then cycle And fits step. global a needs and our activity. production solution top for automation partner
a of growth in opportunities. XXXX we in to we this one best capture ensure we've from to started for sectors our results what that financial and environment ever from in market We meaningfully we're these and deliver year built. our to executing which be the all the strong continue look We more
my over Lindon. call the to concludes formal now and turn That I'll remarks
